Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of $(22.39) per share from the same period last year. The company reported quarterly sales of $3.384 million which beat the analyst consensus estimate of $2.000 million by 69.20 percent. This is a 111.37 percent increase over sales of $1.601 million the same period last year.